Results 31 to 40 of about 95 (52)

Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. [PDF]

PLoS Med, 2020
Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, Guglieri M, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, Kerchner L, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, Gordish-Dressman H, Hagerty L, Dang UJ, Damsker JM, Schwartz BD, Mengle-Gaw LJ, McDonald CM, CINRG VBP15 and DNHS Investigators.   +26 more
europepmc   +1 more source

Cost-effectiveness of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. [PDF]

Prim Care Respir J, 2012
Svensson J, Lundberg J, Olsson P, Stjärne P, Tennvall GR.   +4 more
europepmc   +1 more source

Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. [PDF]

Pharmacol Res, 2018
Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR.   +31 more
europepmc   +1 more source

Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. [PDF]

Eur J Med Res, 2012
Gerber PA, Meller S, Eames T, Buhren BA, Schrumpf H, Hetzer S, Ehmann LM, Budach W, Bölke E, Matuschek C, Wollenberg A, Homey B.   +11 more
europepmc   +1 more source

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. [PDF]

Steroids, 2018
Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, Nagaraju K, Gordish-Dressman H, Damsker JM, McCall JM.   +9 more
europepmc   +1 more source

Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). [PDF]

Support Care Cancer, 2012
Atherton PJ, Burger KN, Loprinzi CL, Neben Wittich MA, Miller RC, Jatoi A, Sloan JA.   +6 more
europepmc   +1 more source

VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. [PDF]

Cell Mol Neurobiol, 2015
Dillingham BC, Knoblach SM, Many GM, Harmon BT, Mullen AM, Heier CR, Bello L, McCall JM, Hoffman EP, Connor EM, Nagaraju K, Reeves EKM, Damsker JM.   +12 more
europepmc   +1 more source

Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. [PDF]

Life Sci Alliance, 2019
Heier CR, Yu Q, Fiorillo AA, Tully CB, Tucker A, Mazala DA, Uaesoontrachoon K, Srinivassane S, Damsker JM, Hoffman EP, Nagaraju K, Spurney CF.   +11 more
europepmc   +1 more source

Adrenal Suppression From Vamorolone and Prednisone in Duchenne Muscular Dystrophy: Results From the Phase 2b Clinical Trial.

J Clin Endocrinol Metab
Ahmet A, Tobin R, Dang UJ, Rooman R, Guglieri M, Clemens PR, Hoffman EP, Ward LM.   +7 more
europepmc   +1 more source

Inhibition of chlorine-induced pulmonary inflammation and edema by mometasone and budesonide. [PDF]

Toxicol Appl Pharmacol, 2013
Chen J, Mo Y, Schlueter CF, Hoyle GW.
europepmc   +1 more source